NCT00017251View on ClinicalTrials.gov

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

January 31, 2004

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
BIOLOGICAL

oblimersen sodium

Given IV

DRUG

carboplatin

Given IV

DRUG

etoposide

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00017251 - Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter